1,2 For patients with visible mucosal abnormalities in Barrett esophagus, focal resection by endoscopic mucosal resection enables increased accuracy of histological grading of the lesion, as well as potentially curative resection of superficial esophageal adenocarcinoma. However, identifying the most appropriate treatment for patients with flat, dysplastic Barrett esophagus has generated debate. In a recent study, van Vilsteren and colleagues attempt to address this issue. 3 To date, endoscopic techniques have focused on either cutting or burning (or freezing) highrisk tissue in patients with Barrett esophagus. Stepwise radical endoscopic resection (SRER) removes all Barrett esophagus by consecutive sessions of endoscopic mucosal resection. By con trast, ablation techniques focus on burning or freezing dysplastic tissues by a variety of methods. As both methods can result in the complete removal of the neoplastic lesion, their relative merits are fiercely contested. Proponents of SRER point to the large resec tion specimen achieved with this method, which enables superior histological grading of the lesion. Compared with mucosal abla tion, SRER also enables an increased depth of tissue destruction, which presumably results in a decreased incidence of residual buried glandular epithelium. Investigators who favor ablative modalities reference the proven effectiveness of these strategies in inducing reversion to neosquamous epi thelium and in decreasing the rate of pro gression to cancer. They further cite the ease of use of ablative modalities and the rela tively low risk of complications, especially strictures, compared with SRER. Therefore, a randomized comparison of SRER and mucosal ablation in the setting of non nodular highgrade dysplasia is desirable and logical.
Against this backdrop, a recent multi center, randomized, controlled trial by van Vilsteren and colleagues assessed the safety of SRER compared with radiofrequency ablation (RFA) with focal endoscopic resection. 3 The trial included patients who had Barrett esophagus <5 cm in length. Participants underwent a maximum of four endoscopic treatments and were then eligible for salvage treatment with an alternative modality. Patients in the RFA arm received salvage therapy with either endoscopic resection or ablation with hot biopsy forceps. In the SRER arm, patients received salvage therapy with either RFA, argon plasma coagulation or ablation with hot biopsy forceps. Patients who under went RFA therapy were treated with the BÂRRX HALO 360 and HALO 90 devices at 40 W/cm 2 and 12 J/cm 2 . Those undergoing SRER were treated in a hemi circumferential pattern with the endoscopic resection cap, multiband mucosectomy or simple snare techniques.
In keeping with prior studies, 1,4-10 there were high rates of complete eradication of neoplastic tissue (96% versus 100% for RFA and SRER, respectively) and intestinal metaplasia (96% versus 92% for RFA and SRER, respectively) among the 47 random ized patients, regardless of the endoscopic therapy received. However, the incidence of complications was markedly different between the two treatment arms. Of patients who underwent SRER, 88% developed a symptomatic esophageal stricture and 
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onequarter (6/25) had scarring and stric tures that prevented further SRER and required salvage treatment with endoscopic ablation to obtain complete eradication of disease. One patient in the SRER arm of the study had an esophageal perforation. By comparison, only 14% of patients who received RFA developed symptomatic strictures and none had perforations. 3 The implications of stricture formation in patients who undergo endoscopic therapy go beyond dysphagia and patient dissatis faction. Such patients are more difficult to monitor for recurrent disease than patients without stricture formation because of the difficulty in visualizing a strictured and scarred lumen. Strictures often necessi tate additional endoscopic procedures for evalua tion and treatment, which increases the risks and costs associated with endo scopic therapy. Not surprisingly, the patients who underwent SRER in this trial required twice the number of endoscopic procedures compared with patients in the RFA arm.
The increased risk of strictures associ ated with using SRER to treat patients with nonnodular dysplastic Barrett esophagus might be tolerable if resection provided an additional benefit. For example, if the use of SRER enabled diagnosis of previously undetected invasive adenocarcinoma, such a finding could clearly change treatment plans. However, patients with nonnodular dysplasia very rarely have invasive cancer. Treatment with ablation might delay the diagnosis of invasive cancer, but is unlikely to change the poor prognosis of nodal disease. The current study by van Vilsteren et al. adds to the growing sentiment that it is unwise to subject patients to a substan tial likelihood of stricture formation by performing SRER for flat dysplasia for the unproven benefit of better outcomes.
Endoscopic mucosal resection and abla tion are complimentary methods. When used judiciously they reduce the risk of esophageal cancer with a tolerable adverse effect profile. The study by van Vilsteren and colleagues further confirms that resec tion of visible mucosal abnormalities and ablation of the remaining Barrett esopha gus provides excellent overall results for the appropriately chosen patient, such as those with nodular highgrade dysplasia. Endoscopic ablation with focal resection of nodular disease offers the benefit of tissue acquisition of the most worrisome endoscopic lesion with a reduced risk of complications when compared with SRER. Although it would be desirable to have the entire precancerous lesion for histological assessment, the additional morbidity associ ated with SRER makes it an inferior choice for those with nonnodular dys plastic Barrett esophagus.
